Identity
- Trade Name
- PRO-TRAC II TACROLIMUS ELISA KIT FDA PMA
- Generic Name
- ENZYME IMMUNOASSAY, TRACROLIMUS FDA PMA
Identifiers
- PMA Number
- P970025 FDA PMA
- FDA Product Code
- MLM FDA PMA
Classification
- Device Class
- Class II FDA PMA
- Legislation / Framework
- 21 CFR Part 862.1678 FDA PMA
- Regulation Number
- 862.1678 FDA PMA
- Advisory Committee
- Clinical Toxicology FDA PMA
- FDA Decision
- APRL FDA PMA
The Pro-Trac II Tacrolimus ELISA Kit is an enzyme immunoassay designed for the quantitative determination of tacrolimus (Prograf, FK506) and its metabolites in human whole blood collected in EDTA or heparin. It functions as an in vitro diagnostic tool to aid in the therapeutic management of liver transplant patients undergoing tacrolimus therapy by providing measurable blood concentration data.
This kit is supplied as a single-use diagnostic reagent intended for use in clinical chemistry laboratories. It requires no special storage conditions beyond those specified in the accompanying instructions, though sterility and proper handling are critical to maintaining assay accuracy. The device is classified under FDA’s Class II regulatory category (MLM product code) and holds a Premarket Approval (PMA) designation (PMA Number: P970025), ensuring compliance with stringent performance and safety standards for in vitro diagnostics.
This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them.
Authorization Coverage (1 country)
Regulatory Authorizations
FDA_PMA
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA PMA | United States | FDA_PMA | P970025 | Class II | Active |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Diasorin Inc.
- FDA Applicant
- DiaSorin, Inc.
Sources (1)
- FDA PMA P970025 24 fields · synced Sep 18, 2026